Pulmonary metastases from colorectal cancer: 25 years of experience

To examine the experience of pulmonary resections for colorectal metastases at the McGill University Health Centre. A chart review. Forty-nine patients treated surgically between 1975 and 1998 for pulmonary metastases from colorectal cancer. Thoracotomy with pulmonary resection. Survival of patients...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Canadian Journal of Surgery 2001-06, Vol.44 (3), p.217-221
Hauptverfasser: Irshad, K, Ahmad, F, Morin, J E, Mulder, D S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To examine the experience of pulmonary resections for colorectal metastases at the McGill University Health Centre. A chart review. Forty-nine patients treated surgically between 1975 and 1998 for pulmonary metastases from colorectal cancer. Thoracotomy with pulmonary resection. Survival of patients with various preoperative and post operative clinical variables. The perioperative death rate was 4%. Overall 5- and 10-year survival rates were 55% and 40% respectively. The mean interval between the initial colonic resection and resection of pulmonary metastases (discase-free interval) was 36 months. The 7 patients who also under went resection of extrapulmonary metastases had a 5-year survival rate of 52%. Significant preoperative variables that carried a poor prognosis included the following: more than one pulmonary lesion, a disease-free interval of less than 2 years, and moderately or poorly differentiated colorectal cancer. The 16 patients who received chemotherapy after their thoracotomy had a 5-year survival rate of 51% compared with 54% for the 33 patients who did not receive chemotherapy. Recurrent resections of pulmonary lesions did not reduce survival. Pulmonary resection for metastatic colorectal cancer is both effective and safe. Resectable extrapulmonary metastases and pulmonary recurrence should not preclude lung resection. Postoperative chemotherapy has no survival benefit. Preoperative variables should guide the clinician when considering surgical intervention.
ISSN:0008-428X
1488-2310